Grifols S.A.

Company Overview

Grifols S.A. is an international company that manufactures and supplies protein therapies for patients and provides medical care tools to hospitals, pharmacies and other healthcare professionals. The three prime divisions of the company are bioscience, diagnostic and hospital. The company provides innovative products as well as services to medical professionals in more than 90 countries. Grifols is a leading manufacturer of plasma-derived therapies, which are essentially used in the treatment of patients suffering from rare genetic diseases or severe infections.

Grifols became the first company to start production of an anti-SARS-CoV-2 hyperimmune immunoglobulin. It did this by leveraging its broad expertise and experience in the development of specific immunoglobulins used in the treatment and prevention of infections, which had been applied to previous healthcare emergencies like the Ebola outbreak.

Financial Highlights (FY 2023)

Company's Business Segments

• Biopharma : Segment includes activities related to products derived from human plasma for therapeutic use.
• Diagnostic : Segment includes diagnostic testing equipment, reagents and other equipment.
• Bio Supplies : Segment includes transactions related to biological products for non-therapeutic use.
• Others : The segment includes activities related to manufacturing services to third parties, plasma sales and research activities related to third parties. It also includes pharmaceutical products manufactured by the Group and intended for hospital pharmacies, as well as the marketing of products that complement the Group's own products.